Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2226
PUT
Lowe's Companies
LOW
$101B
| $4.85M | ﹤0.01% |
20,100
-329,000
| -94% | -$79M |
2024 Q3
5 quarters
|
|
2227
PUT
Deere & Co
DE
$185B
| $4.84M | ﹤0.01% |
10,400
| – | – |
2024 Q3
5 quarters
|
|
2228
ImmunityBio
IBRX
$10.8B
| $4.84M | ﹤0.01% |
2,444,163
+1,516,476
| +163% | +$3.44M |
2022 Q1
15 quarters
|
|
2229
Howard Hughes
HHH
$4.31B
| $4.84M | ﹤0.01% |
60,655
-183
| -0.3% | -$15.2K |
2023 Q4
8 quarters
|
|
2230
Greif
GEF
$4.67B
| $4.84M | ﹤0.01% |
71,430
-4,541
| -6% | -$284K |
2013 Q2
50 quarters
|
|
2231
Chefs' Warehouse
CHEF
$4.65B
| $4.82M | ﹤0.01% |
77,398
+13,220
| +21% | +$795K |
2013 Q2
50 quarters
|
|
2232
Agilysys
AGYS
$2.82B
| $4.8M | ﹤0.01% |
40,376
+3,310
| +9% | +$398K |
2016 Q1
39 quarters
|
|
2233
Collegium Pharmaceutical
COLL
$713M
| $4.8M | ﹤0.01% |
103,609
+29,578
| +40% | +$1.24M |
2015 Q2
42 quarters
|
|
2234
Stoke Therapeutics
STOK
$1.62B
| $4.79M | ﹤0.01% |
150,945
+43,222
| +40% | +$1.3M |
2019 Q2
26 quarters
|
|
|
BBT
2235
Beacon Financial Corp
BBT
$2.38B
| $4.79M | ﹤0.01% |
181,604
+56,083
| +45% | +$1.42M |
2016 Q3
37 quarters
|
|
2236
Unifirst Corp
UNF
$4.59B
| $4.79M | ﹤0.01% |
24,811
+1,383
| +6% | +$233K |
2013 Q2
50 quarters
|
|
2237
Marcus Corp
MCS
$837M
| $4.78M | ﹤0.01% |
307,970
+15,388
| +5% | +$229K |
2016 Q1
39 quarters
|
|
2238
Clear Secure
YOU
$4.23B
| $4.77M | ﹤0.01% |
135,960
+14,458
| +12% | +$492K |
2022 Q1
15 quarters
|
|
2239
Diageo
DEO
$46.4B
| $4.76M | ﹤0.01% |
55,221
+54,698
| +10,459% | +$5.04M |
2024 Q3
5 quarters
|
|
2240
CBIZ
CBZ
$3.01B
| $4.75M | ﹤0.01% |
94,163
+4,066
| +5% | +$214K |
2013 Q2
50 quarters
|
|
|
NEE.PRS
2241
NextEra Energy 7.299% Corporate Units
NEE.PRS
$1.97B
| $4.75M | ﹤0.01% |
91,728
+25,000
| +37% | +$1.33M |
2024 Q2
6 quarters
|
|
2242
DNOW Inc
DNOW
$2.9B
| $4.75M | ﹤0.01% |
358,304
+10,797
| +3% | +$152K |
2014 Q2
46 quarters
|
|
|
SARO
2243
StandardAero Inc
SARO
$7.02B
| $4.74M | ﹤0.01% |
165,320
-312,182
| -65% | -$8.5M |
2024 Q4
4 quarters
|
|
|
STUB
2244
PUT
StubHub Holdings
STUB
$2.1B
| $4.74M | ﹤0.01% |
+350,000
| New | +$5.5M |
2025 Q4
0 quarters
|
|
2245
Urban Edge Properties
UE
$2.49B
| $4.74M | ﹤0.01% |
246,753
+15,974
| +7% | +$310K |
2015 Q1
43 quarters
|
|
2246
Louisiana-Pacific
LPX
$4.63B
| $4.73M | ﹤0.01% |
58,570
-27,255
| -32% | -$2.3M |
2013 Q2
50 quarters
|
|
2247
Nexstar Media Group
NXST
$4.88B
| $4.72M | ﹤0.01% |
23,231
-24,444
| -51% | -$4.77M |
2016 Q1
39 quarters
|
|
|
APLS
2248
DELISTED
Apellis Pharmaceuticals
APLS
| $4.72M | ﹤0.01% |
187,712
-81,815
| -30% | -$1.92M |
2017 Q4
32 quarters
|
|
2249
Hamilton Lane
HLNE
$4.76B
| $4.71M | ﹤0.01% |
35,048
-29,719
| -46% | -$3.74M |
2017 Q2
34 quarters
|
|
2250
Wave Life Sciences
WVE
$753M
| $4.71M | ﹤0.01% |
276,781
+3,907
| +1% | +$39.7K |
2022 Q3
13 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.